Laurence B Katz1,2, Lorna Stewart3,4, Brian Guthrie3,4, Hilary Cameron5. 1. LifeScan Global Corp., Wayne, PA, USA. 2. LifeScan Inc., Malvern, PA, USA. 3. LifeScan Global Corp., Inverness, UK. 4. LifeScan Scotland Ltd., Inverness, UK. 5. 4 The Stables, Knockomie, Forres, UK.
Abstract
BACKGROUND: Accurate self-monitoring of blood glucose (SMBG) is a key component of effective self-management of glycemic control. METHODS: The OneTouch Verio Reflect and OneTouch Ultra Plus Reflect BG monitoring systems were evaluated for accuracy in a clinical setting. Subjects also used the meters for a one-week trial period and reported their level of satisfaction with meter features. RESULTS: Both systems were accurate over a wide glucose range and met lay user and system accuracy BG standards described in ISO15197:2015. Subjects felt that the features of a meter with a dynamic color range indicator and personalized guidance, insight, and encouragement could provide significant benefits to them in the management of their diabetes. CONCLUSIONS: Both meter systems were accurate over a wide glucose range and the features of the meter and messages were well received by patients in a short take-home trial. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT0351542.
BACKGROUND: Accurate self-monitoring of blood glucose (SMBG) is a key component of effective self-management of glycemic control. METHODS: The OneTouch Verio Reflect and OneTouch Ultra Plus Reflect BG monitoring systems were evaluated for accuracy in a clinical setting. Subjects also used the meters for a one-week trial period and reported their level of satisfaction with meter features. RESULTS: Both systems were accurate over a wide glucose range and met lay user and system accuracy BG standards described in ISO15197:2015. Subjects felt that the features of a meter with a dynamic color range indicator and personalized guidance, insight, and encouragement could provide significant benefits to them in the management of their diabetes. CONCLUSIONS: Both meter systems were accurate over a wide glucose range and the features of the meter and messages were well received by patients in a short take-home trial. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT0351542.
Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Robert R Henry; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez Journal: Endocr Pract Date: 2016-01 Impact factor: 3.443
Authors: David C Klonoff; Joan Lee Parkes; Boris P Kovatchev; David Kerr; Wendy C Bevier; Ronald L Brazg; Mark Christiansen; Timothy S Bailey; James H Nichols; Michael A Kohn Journal: Diabetes Care Date: 2018-06-13 Impact factor: 19.112
Authors: William H Polonsky; Lawrence Fisher; Charles H Schikman; Deborah A Hinnen; Christopher G Parkin; Zhihong Jelsovsky; Bettina Petersen; Matthias Schweitzer; Robin S Wagner Journal: Diabetes Care Date: 2011-02 Impact factor: 19.112
Authors: C L Morgan; A Griffin; G H Chamberlain; A Turkiendorf; P McEwan; L M Evans; D R Owens Journal: Diabetes Ther Date: 2010-07-28 Impact factor: 2.945